Aparna Brown, MD
Endocrinology, Diabetes & Metabolism · Toledo, OHNPI 1174570337
Payments from drug & device makers
Across 190 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$394
- Novo Nordisk$273
- Tandem Diabetes Care, Inc.$258
- Lilly USA, LLC$224
- Sanofi-aventis U.S. LLC$222
- Amgen$156
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,818100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 24 | $394 |
| Novo Nordisk | 22 | $273 |
| Tandem Diabetes Care, Inc. | 19 | $258 |
| Lilly USA, LLC | 21 | $224 |
| Sanofi-aventis U.S. LLC | 14 | $222 |
| Amgen | 11 | $156 |
| Medtronic | 12 | $153 |
| Abbott | 7 | $148 |
| Xeris Pharmaceuticals, Inc. | 5 | $110 |
| Boehringer Ingelheim | 5 | $96 |
| Johnson & Johnson | 5 | $95 |
| AstraZeneca | 7 | $90 |
| Insulet Corporation | 5 | $77 |
| Shire North American Group Inc | 4 | $61 |
| AbbVie | 2 | $48 |
| Radius Health, Inc. | 3 | $47 |
| Mannkind Corporation | 3 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $39 |
| Antares Pharma, Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Merck | 2 | $24 |
| Pfizer | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| BETA Bionics, Inc. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Sandoz | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$2,818 in reported general payments places this provider in the 60th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 263 | $443,608 |
| TrulicityDulaglutide | 127 | $207,591 |
| JanuviaSitagliptin Phosphate | 131 | $175,646 |
| JardianceEmpagliflozin | 91 | $113,713 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 107 | $109,114 |
| MounjaroTirzepatide | 81 | $103,389 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 129 | $78,792 |
| FarxigaDapagliflozin Propanediol | 44 | $54,721 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 281 | $53,757 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 53 | $49,590 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $47,650 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $45,638 |
| Humalog Kwikpen U-100Insulin Lispro | 78 | $40,141 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $38,194 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $35,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Novolog Mix 70-30 | $273 | $465,217314 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $224 | $317,885228 claims |
| MerckJanuvia, Janumet Xr | $24 | $284,760238 claims |
| Boehringer IngelheimJardiance, Tradjenta | $96 | $131,510113 claims |
| AstraZenecaFarxiga | $90 | $54,72144 claims |
| Sanofi-aventis U.S. LLCAdmelog, Lantus | $222 | $14,04942 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $12,388889 claims |
| AbbVieSynthroid | $48 | $7,377153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Toledo
- Bhaskar GundaboluToledo$471K
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.